Provided by Tiger Trade Technology Pte. Ltd.

Amylyx Pharmaceuticals

33.75
-0.9900-2.85%
Post-market: 33.750.00000.00%19:58 EDT
Volume:2.73M
Turnover:91.96M
Market Cap:3.75B
PE:-23.59
High:35.09
Open:34.77
Low:32.98
Close:34.74
52wk High:41.14
52wk Low:9.15
Shares:111.19M
Float Shares:109.51M
Volume Ratio:1.13
T/O Rate:2.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4309
EPS(LYR):-1.5305
ROE:-74.73%
ROA:-44.13%
PB:15.69
PE(LYR):-22.05

Loading ...

Press Release: Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Dow Jones
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Amylyx management participates in Bank of America Health Care Conference fireside chat

Reuters
·
May 06

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults With Post-Bariatric Hypoglycemia

THOMSON REUTERS
·
May 05

Amylyx Pharmaceuticals Inc - Avexitide Phase 3 Lucidity Trial Topline Data Readout Anticipated in Q3 2026

THOMSON REUTERS
·
May 05

Amylyx Pharmaceuticals Inc - Commercial Launch of Avexitide Anticipated in 2027 IF Approved

THOMSON REUTERS
·
May 05

Amylyx Pharmaceuticals to report first-quarter financial results, host conference call

Reuters
·
Apr 30

Amylyx Pharmaceuticals announces annual shareholder meeting via webcast

Reuters
·
Apr 23

Amylyx to present at Needham Virtual Healthcare Conference

Reuters
·
Apr 08

A Look At Amylyx Pharmaceuticals (AMLX) Valuation As Avexitide Hits A Key Phase 3 LUCIDITY Milestone

Simply Wall St.
·
Apr 07

Amylyx Pharmaceuticals Price Target Maintained With a $34.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 25

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Economic Data Releases

MT Newswires Live
·
Mar 24

Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide

TIPRANKS
·
Mar 24

Amylyx completes enrollment of 78 participants in Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia

Reuters
·
Mar 24

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Lucidity Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

THOMSON REUTERS
·
Mar 24

Amylyx Pharmaceuticals Inc - Topline Data Readout for Lucidity Trial Anticipated in Q3 2026

THOMSON REUTERS
·
Mar 24

Amylyx Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 19

Stock Track | Amylyx Pharmaceuticals Soars 5.24% Intraday After H.C. Wainwright Raises Price Target to $34

Stock Track
·
Mar 05

Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 05

Amylyx price target raised to $34 from $28 at H.C. Wainwright

TIPRANKS
·
Mar 04